Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.62 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 9/20 | 0.46 |
| ▸ | CA9 | Q16790 | 8/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30578 | 0.97 | — | — | |
| SCHEMBL3259452 | 0.94 | CA2 (0.62) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL277384 | 0.94 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL4620374 | 0.94 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL11963130 | 0.94 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL8359972 | 0.94 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL17838038 | 0.94 | CA2 (0.62) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL75573 | 0.94 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL57043 | 0.94 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL277526 | 0.94 | CA2 (0.70) | CA2FAAHCA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268643-B1 | DIOXOLANE AND DIOXOLANONE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8138171-B2 | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110020277-A1 | Dioxolane and Dioxolanone Fused Indolobenzadiazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2268643-A1 | DIOXOLANE AND DIOXOLANONE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009120890-A1 | DIOXOLANE AND DIOXOLANONE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020277-A1 | Dioxolane and Dioxolanone Fused Indolobenzadiazepine HCV NS5B Inhibitors | SQLE, DHX15, FDFT1 | CA2 4808/4885FAAH 1118/4885CA1 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.